Kato Y
Int J Clin Oncol. 2025; .
PMID: 39985645
DOI: 10.1007/s10147-025-02721-5.
Kim J, Gilbert J, Lv W, Du P, Pan H
Bioact Mater. 2024; 45:363-387.
PMID: 39687558
PMC: 11647666.
DOI: 10.1016/j.bioactmat.2024.11.020.
Mitea G, Schroder V, Iancu I, Miresan H, Iancu V, Bucur L
Cancers (Basel). 2024; 16(21).
PMID: 39518052
PMC: 11545343.
DOI: 10.3390/cancers16213612.
Boichuk S, Dunaev P, Galembikova A, Valeeva E
Cancers (Basel). 2024; 16(17).
PMID: 39272961
PMC: 11394061.
DOI: 10.3390/cancers16173103.
Lei X, Li Z, Huang M, Huang L, Huang Y, Lv S
J Exp Clin Cancer Res. 2024; 43(1):83.
PMID: 38493151
PMC: 10944600.
DOI: 10.1186/s13046-024-03003-0.
Identification of key genes modules linking diabetic retinopathy and circadian rhythm.
Ling F, Zhang C, Zhao X, Xin X, Zhao S
Front Immunol. 2023; 14:1260350.
PMID: 38124748
PMC: 10730663.
DOI: 10.3389/fimmu.2023.1260350.
Fibroblast growth factor 2.
Nickle A, Ko S, Merrill A
Differentiation. 2023; 139:100733.
PMID: 37858405
PMC: 11009566.
DOI: 10.1016/j.diff.2023.10.001.
The Safety Profile of Hepatectomy Following Preoperative Systemic Therapy with Lenvatinib Plus Anti-PD-1 Antibodies Versus Hepatectomy Alone in Patients With Hepatocellular Carcinoma.
Shen Y, Huang C, Zhu X, Xu M, Chen Z, Tan C
Ann Surg Open. 2023; 3(2):e163.
PMID: 37601608
PMC: 10431521.
DOI: 10.1097/AS9.0000000000000163.
Neutrophil extracellular traps promote angiogenesis in gastric cancer.
Yang S, Sun B, Li J, Li N, Zhang A, Zhang X
Cell Commun Signal. 2023; 21(1):176.
PMID: 37480055
PMC: 10362668.
DOI: 10.1186/s12964-023-01196-z.
Tumor Vasculature as an Emerging Pharmacological Target to Promote Anti-Tumor Immunity.
Tzeng H, Huang Y
Int J Mol Sci. 2023; 24(5).
PMID: 36901858
PMC: 10002465.
DOI: 10.3390/ijms24054422.
Exosomal cargos-mediated metabolic reprogramming in tumor microenvironment.
Tan S, Yang Y, Yang W, Han Y, Huang L, Yang R
J Exp Clin Cancer Res. 2023; 42(1):59.
PMID: 36899389
PMC: 9999652.
DOI: 10.1186/s13046-023-02634-z.
Integrin-specific hydrogels for growth factor-free vasculogenesis.
Moreira H, Rodrigues D, Freitas-Ribeiro S, da Silva L, Morais A, Jarnalo M
NPJ Regen Med. 2022; 7(1):57.
PMID: 36167724
PMC: 9515164.
DOI: 10.1038/s41536-022-00253-4.
Evaluation of the Effect of the Fibroblast Growth Factor Type 2 (FGF-2) Administration on Placental Gene Expression in a Murine Model of Preeclampsia Induced by L-NAME.
Martinez-Fierro M, Garza-Veloz I, Castaneda-Lopez M, Wasike D, Castruita-De la Rosa C, Rodriguez-Sanchez I
Int J Mol Sci. 2022; 23(17).
PMID: 36077527
PMC: 9456139.
DOI: 10.3390/ijms231710129.
Molecular Mechanisms and Future Implications of VEGF/VEGFR in Cancer Therapy.
Patel S, Nilsson M, Le X, Cascone T, Jain R, Heymach J
Clin Cancer Res. 2022; 29(1):30-39.
PMID: 35969170
PMC: 10274152.
DOI: 10.1158/1078-0432.CCR-22-1366.
Dynamic Interactions between Tumor Cells and Brain Microvascular Endothelial Cells in Glioblastoma.
Testa E, Palazzo C, Mastrantonio R, Viscomi M
Cancers (Basel). 2022; 14(13).
PMID: 35804908
PMC: 9265028.
DOI: 10.3390/cancers14133128.
Lenvatinib dose, efficacy, and safety in the treatment of multiple malignancies.
Motzer R, Taylor M, Evans T, Okusaka T, Glen H, Lubiniecki G
Expert Rev Anticancer Ther. 2022; 22(4):383-400.
PMID: 35260027
PMC: 9484451.
DOI: 10.1080/14737140.2022.2039123.
Tumours modulate the systemic vascular response to anti-angiogenic therapy.
Hargreaves A, Barry S, Bigley A, Kendrew J, Price S
J Appl Toxicol. 2022; 42(8):1371-1384.
PMID: 35152467
PMC: 9543901.
DOI: 10.1002/jat.4301.
Is There Still a Place for Tyrosine Kinase Inhibitors for the Treatment of Hepatocellular Carcinoma at the Time of Immunotherapies? A Focus on Lenvatinib.
Decraecker M, Toulouse C, Blanc J
Cancers (Basel). 2021; 13(24).
PMID: 34944930
PMC: 8699782.
DOI: 10.3390/cancers13246310.
FGF/FGFR-Dependent Molecular Mechanisms Underlying Anti-Cancer Drug Resistance.
Szymczyk J, Sluzalska K, Materla I, Opalinski L, Otlewski J, Zakrzewska M
Cancers (Basel). 2021; 13(22).
PMID: 34830951
PMC: 8616288.
DOI: 10.3390/cancers13225796.
Inhibition of FGFR Reactivates IFNγ Signaling in Tumor Cells to Enhance the Combined Antitumor Activity of Lenvatinib with Anti-PD-1 Antibodies.
Adachi Y, Kamiyama H, Ichikawa K, Fukushima S, Ozawa Y, Yamaguchi S
Cancer Res. 2021; 82(2):292-306.
PMID: 34753772
PMC: 9397636.
DOI: 10.1158/0008-5472.CAN-20-2426.